Regenxbio (RGNX) Misses Q3 EPS by 29c; Reports $533.5M of Cash and Cash Equivalents

Regenxbio (NASDAQ: RGNX) reported Q3 EPS of ($1.37), $0.29 worse than the analyst estimate of ($1.08). Revenue for the quarter came in at $30.8 million versus the consensus estimate of $41.46 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Regenxbio Inc. (RGNX) PT Raised to $32 at Baird
• REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
• Goldman "broadly" raises estimates for LTL and truckload stocks